SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
Consumer |
Outlook
Consumer |
Outlook
Consumer |
Update
Consumer |
Update
Daniel Kruse
CEO
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (2.3) | (7.9) | 57.8 |
Relative | (3.6) | (16.2) | 23.5 |
52 week high/low | €13.9/€2.9 |
SynBiotic has built up a leading platform company that spans the hemp and cannabis industry to cover the full value chain, from cultivation through to sales. Management buys and builds ventures that create and market hemp, cannabis and cannabinoid products for both medical and recreational use, while continually seeking investments in exciting new verticals. Recreational cannabis use has recently been partially legalised in Germany, while the same legislative changes have benefited the medicinal market. Having built its platform prior to these changes, SynBiotic is seeing its investments bear fruit and we believe it is well-positioned for any further relaxation in cannabis legalisation in Germany.